YU47903A - Proizvodi steroidnih hormona i postupci za njihovo dobijanje - Google Patents

Proizvodi steroidnih hormona i postupci za njihovo dobijanje

Info

Publication number
YU47903A
YU47903A YU47903A YUP47903A YU47903A YU 47903 A YU47903 A YU 47903A YU 47903 A YU47903 A YU 47903A YU P47903 A YUP47903 A YU P47903A YU 47903 A YU47903 A YU 47903A
Authority
YU
Yugoslavia
Prior art keywords
products
methods
steroid hormone
hormone
excipient
Prior art date
Application number
YU47903A
Other languages
English (en)
Inventor
Thomas Schultz
Bradley Clark
Angela Falzone
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of YU47903A publication Critical patent/YU47903A/sh
Publication of RS50414B publication Critical patent/RS50414B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prikazani pronalazak se odnosi na proizvode stereoidnih hormona, kao što su oralna kontraceptivna sredstva, koji uključujući bar jedan aktivni steroidni sastojak pomešan sa ekscipijentom i imaju poboljšane osobine rastvaranja i brzine oslobađanja. Pronalazak se dalje odnosi na postupak za pripremanje takvih proizvoda stereoidnih hormona, gde je smeša hormona i ekscipijenta podvrgnuta dovoljnoj mehaničkoj energiji da bi se dobila mešavina praha u kojoj hormon je stabilizovan sa ekscipijentom u suštinski ne kristalnom obliku. [The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone and the excipient is subjected to sufficient mechanical energy to form a powder blend wherein the hormone is stabilized by the excipient in substantially non-crystalline form.
YUP-479/03A 2000-12-14 2001-12-13 Proizvodi steroidnih hormona i postupci za njihovo dobijanje RS50414B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25566900P 2000-12-14 2000-12-14

Publications (2)

Publication Number Publication Date
YU47903A true YU47903A (sh) 2006-08-17
RS50414B RS50414B (sr) 2009-12-31

Family

ID=22969374

Country Status (31)

Country Link
US (4) US7867990B2 (sh)
EP (2) EP1361881B1 (sh)
KR (1) KR100899032B1 (sh)
CN (1) CN1290507C (sh)
AT (2) ATE434439T1 (sh)
AU (2) AU2002227421B2 (sh)
BG (1) BG66178B1 (sh)
BR (1) BRPI0116793B8 (sh)
CA (1) CA2431521E (sh)
CR (1) CR7022A (sh)
CY (1) CY1109404T1 (sh)
CZ (1) CZ306435B6 (sh)
DE (2) DE60114467T2 (sh)
DK (2) DK1361881T3 (sh)
EC (1) ECSP034654A (sh)
EE (1) EE05358B1 (sh)
ES (2) ES2253451T3 (sh)
HK (2) HK1057174A1 (sh)
HU (1) HU230400B1 (sh)
IL (2) IL156423A0 (sh)
ME (1) ME00339B (sh)
MX (1) MXPA03005339A (sh)
NO (2) NO334341B1 (sh)
NZ (1) NZ526517A (sh)
PT (1) PT1591121E (sh)
RS (1) RS50414B (sh)
RU (1) RU2286155C2 (sh)
SK (1) SK288222B6 (sh)
UA (1) UA77404C2 (sh)
WO (1) WO2002047693A2 (sh)
ZA (1) ZA200305342B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
ES2253451T3 (es) * 2000-12-14 2006-06-01 Ortho-Mcneil Pharmaceutical, Inc. Productos a base de hormona esteroide y sus procedimientos de fabricacion.
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
PL1820494T3 (pl) * 2003-06-13 2010-07-30 Skendi Finance Ltd Mikrocząstki składające się z estradiolu i cholesterolu
TWI428271B (zh) * 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
EA018974B9 (ru) * 2008-02-05 2014-04-30 Харбор Терапьютикс, Инк. Твердые лекарственные формы
AU2009231589B2 (en) 2008-04-03 2013-11-07 Neurmedix, Inc. Solid state forms of a pharmaceutical
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
US10993879B2 (en) 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
WO2011097571A2 (en) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CN102793929B (zh) * 2012-09-07 2013-12-11 上海奥科达生物医药科技有限公司 一种制备稳定非晶态药物制剂的方法
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20200129438A1 (en) * 2018-10-31 2020-04-30 Edenbridge Pharmaceuticals, LLC Finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2648700A (en) * 1946-11-02 1953-08-11 Searle & Co 2-methyl-2,7-dihydroxy-octahydrophenanthrene-1-propionic acid and derivatives thereof
US2636042A (en) * 1949-07-08 1953-04-21 S B Penick And Company Water-soluble hormone compounds
US2642427A (en) * 1951-08-01 1953-06-16 Abbott Lab Piperazine salts of cyclopentanopolyhydrophenanthrene-3-monosulfates
US2666066A (en) * 1951-09-28 1954-01-12 Abbott Lab Ethylenediamine salts of cyclopen-tanopolyhydrophenanthrene-3-monosulfates
US3032469A (en) * 1958-05-02 1962-05-01 Charles E Frosst & Company Long acting steroid compounds
US3568828A (en) * 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3691212A (en) * 1970-04-24 1972-09-12 British Drug Houses Ltd 17alpha-(1',3'-alkadiynyl)-17beta-acyloxy(17beta-aroyloxy) steroids
US4046874A (en) * 1974-02-13 1977-09-06 Mead Johnson & Company Soapless shave composition
US4511551A (en) * 1982-11-18 1985-04-16 Unique Technologies, Incorporated Method and composition for the detection of a precancerous or leukemic condition in mammals
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
EP0193871B1 (en) * 1985-03-07 1989-05-31 Teikoku Hormone Mfg. Co., Ltd. 2-oxa- or aza-pregnane compounds
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
US5344392A (en) * 1990-09-28 1994-09-06 Baxter International Inc. Method and apparatus for preparation of solutions from concentrates
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
DE69207863T2 (de) * 1991-11-13 1996-06-05 Glaxo Canada Vorrichtung zur kontrollierten Wirkstoffreigabe
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
IT1270831B (it) * 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
AR004178A1 (es) 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
ATE271386T1 (de) * 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
ES2253451T3 (es) * 2000-12-14 2006-06-01 Ortho-Mcneil Pharmaceutical, Inc. Productos a base de hormona esteroide y sus procedimientos de fabricacion.

Also Published As

Publication number Publication date
NO20032708D0 (no) 2003-06-13
BRPI0116793B1 (pt) 2015-06-23
US20110046095A1 (en) 2011-02-24
UA77404C2 (en) 2006-12-15
ECSP034654A (es) 2003-07-25
DE60114467T2 (de) 2006-07-20
ES2253451T3 (es) 2006-06-01
CY1109404T1 (el) 2014-07-02
ATE307591T1 (de) 2005-11-15
PT1591121E (pt) 2009-07-20
EP1591121A1 (en) 2005-11-02
US20140309204A1 (en) 2014-10-16
DK1361881T3 (da) 2006-02-20
WO2002047693A2 (en) 2002-06-20
CZ20031896A3 (en) 2004-03-17
SK288222B6 (sk) 2014-09-04
CZ306435B6 (cs) 2017-01-25
EE200300229A (et) 2003-08-15
NO334341B1 (no) 2014-02-10
SK8802003A3 (en) 2004-04-06
US20110046099A1 (en) 2011-02-24
RU2286155C2 (ru) 2006-10-27
CA2431521E (en) 2013-04-16
CR7022A (es) 2009-02-23
HK1083457A1 (en) 2006-07-07
CN1290507C (zh) 2006-12-20
DE60114467D1 (de) 2005-12-01
HU230400B1 (hu) 2016-04-28
BR0116793A (pt) 2004-01-27
ZA200305342B (en) 2004-10-11
MEP48808A (en) 2011-02-10
EP1361881A2 (en) 2003-11-19
BG66178B1 (bg) 2011-11-30
BRPI0116793B8 (pt) 2021-05-25
NO20032708L (no) 2003-07-04
IL156423A0 (en) 2004-01-04
CA2431521A1 (en) 2002-06-20
EP1591121B1 (en) 2009-06-24
US20020173669A1 (en) 2002-11-21
KR100899032B1 (ko) 2009-05-21
IL156423A (en) 2010-04-29
DE60139087D1 (de) 2009-08-06
HUP0400646A3 (en) 2012-08-28
EP1361881B1 (en) 2005-10-26
US7867990B2 (en) 2011-01-11
DK1591121T3 (da) 2009-10-05
RS50414B (sr) 2009-12-31
HUP0400646A2 (hu) 2004-06-28
ME00339B (me) 2011-05-10
BG107958A (bg) 2004-11-30
CN1489468A (zh) 2004-04-14
AU2742102A (en) 2002-06-24
NO20131334L (no) 2003-07-04
KR20030061856A (ko) 2003-07-22
EE05358B1 (et) 2010-12-15
ES2327538T3 (es) 2009-10-30
NZ526517A (en) 2005-09-30
MXPA03005339A (es) 2004-03-26
RU2003121240A (ru) 2005-02-10
HK1057174A1 (en) 2004-03-19
ATE434439T1 (de) 2009-07-15
WO2002047693A3 (en) 2002-11-07
AU2002227421B2 (en) 2007-08-23
CA2431521C (en) 2010-03-16

Similar Documents

Publication Publication Date Title
AU2742102A (en) Steroid hormone products and methods for preparing them
WO2004110408A3 (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
GB9700878D0 (en) Dosage forms and method for ameliorating male erectile dysfunction
RS50008B (sr) Antifungalna oralna kompozicija koja sadrži itrakonazol i postupak za dobijanje iste
DE602005024470D1 (de) Verfahren zur Herstellung von Drospirenon
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
GEP20053654B (en) Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
AP1625A (en) Hormonal composition based on a progesterone and an oestrogen and use thereof.
YU18099A (sh) Hormonalni preparat koji sadrži jedinjenje estrogena i progestativno jedinjenje
YU13902A (sh) Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
TW200640468A (en) Pharmaceutical product for oral contraception
ES2126474A1 (es) Procedimiento para la preparacion de composiciones orales que contienn quinolonas
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.